Ultragenyx Stock Alpha and Beta Analysis
| RARE Stock | USD 39.34 0.09 0.23% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Ultragenyx. It also helps investors analyze the systematic and unsystematic risks associated with investing in Ultragenyx over a specified time horizon. Remember, high Ultragenyx's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Ultragenyx's market risk premium analysis include:
Beta 0.92 | Alpha (0.13) | Risk 2.48 | Sharpe Ratio (0.08) | Expected Return (0.21) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Ultragenyx |
Ultragenyx Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Ultragenyx market risk premium is the additional return an investor will receive from holding Ultragenyx long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Ultragenyx. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Ultragenyx's performance over market.| α | -0.13 | β | 0.92 |
Ultragenyx expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Ultragenyx's Buy-and-hold return. Our buy-and-hold chart shows how Ultragenyx performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Ultragenyx Market Price Analysis
Market price analysis indicators help investors to evaluate how Ultragenyx stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Ultragenyx shares will generate the highest return on investment. By understating and applying Ultragenyx stock market price indicators, traders can identify Ultragenyx position entry and exit signals to maximize returns.
Ultragenyx Return and Market Media
The median price of Ultragenyx for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 43.27 with a coefficient of variation of 5.76. The daily time series for the period is distributed with a sample standard deviation of 2.49, arithmetic mean of 43.16, and mean deviation of 1.84. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 11727 shares by Kakkis Emil D of Ultragenyx at 42.23 subject to Rule 16b-3 | 12/30/2024 |
2 | Gene Therapy Market to Hit Valuation of US 42.26 Billion By 2033 Astute Analytica | 01/02/2025 |
3 | Disposition of 9806 shares by Parschauer Karah Herdman of Ultragenyx at 45.0 subject to Rule 16b-3 | 01/21/2025 |
4 | Ultragenyx Pharmaceutical Inc Reports Q4 2024 Revenue of 165 Million, Exceeding Estimates EPS ... | 02/13/2025 |
5 | Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A | 02/18/2025 |
6 | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635 | 02/19/2025 |
7 | Ultragenyx Pharmaceutical Inc Announces Participation in Upcoming Investor Conferences | 02/25/2025 |
8 | Disposition of 760 shares by Parschauer Karah Herdman of Ultragenyx at 42.75 subject to Rule 16b-3 | 02/27/2025 |
9 | Disposition of 141 shares by Theodore Huizenga of Ultragenyx at 42.92 subject to Rule 16b-3 | 03/03/2025 |
10 | Acquisition by Howard Horn of 15653 shares of Ultragenyx subject to Rule 16b-3 | 03/04/2025 |
11 | Global Cell and Gene Therapy Manufacturing Market to Reach USD 10 Billion by 2032 DelveInsight | 03/05/2025 |
12 | Global Genome Editing Market to Grow Rapidly at a CAGR 13 percent by 2032 DelveInsight | 03/06/2025 |
13 | Candriam S.C.A. Sells 38,835 Shares of Ultragenyx Pharmaceutical Inc. | 03/07/2025 |
14 | Ultragenyx CFO Makes a Bold Stock Move - TipRanks | 03/10/2025 |
15 | Disposition of 7500 shares by Fust Matthew K of Ultragenyx at 50.88 subject to Rule 16b-3 | 03/13/2025 |
About Ultragenyx Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Ultragenyx or other stocks. Alpha measures the amount that position in Ultragenyx has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Dividend Yield | 0.0031 | 0.002755 | Price To Sales Ratio | 6.8 | 6.46 |
Ultragenyx Upcoming Company Events
As portrayed in its financial statements, the presentation of Ultragenyx's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ultragenyx's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Ultragenyx's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Ultragenyx. Please utilize our Beneish M Score to check the likelihood of Ultragenyx's management manipulating its earnings.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Ultragenyx
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Ultragenyx Backtesting, Ultragenyx Valuation, Ultragenyx Correlation, Ultragenyx Hype Analysis, Ultragenyx Volatility, Ultragenyx History and analyze Ultragenyx Performance. For information on how to trade Ultragenyx Stock refer to our How to Trade Ultragenyx Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Ultragenyx technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.